Tissue-type plasminogen activator's 10% one-year edge
Publication
, Journal Article
Williams, PA; Califf, RM; Topol, EJ
Published in: Cardiology Review
December 1, 1997
In this trial, 41,021 acute myocardial infarction patients were randomized to one of four thrombolytic regimens. Patients who received accelerated tissue-type plasminogen activator had a significantly lower one- year mortality rate (9.1%) than those who received streptokinase with subcutaneous heparin (10.1%), streptokinase with intravenous heparin (10.1%), or combination plasminogen activator and streptokinase therapy (9.9%). Translating the results into lives saved shows that the use of accelerated tissue-type plasminogen activator can save 10 more lives per 1,000 patients treated than streptokinase regimens.
Duke Scholars
Published In
Cardiology Review
ISSN
1092-6607
Publication Date
December 1, 1997
Volume
14
Issue
2
Start / End Page
41 / 46
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Williams, P. A., Califf, R. M., & Topol, E. J. (1997). Tissue-type plasminogen activator's 10% one-year edge. Cardiology Review, 14(2), 41–46.
Williams, P. A., R. M. Califf, and E. J. Topol. “Tissue-type plasminogen activator's 10% one-year edge.” Cardiology Review 14, no. 2 (December 1, 1997): 41–46.
Williams PA, Califf RM, Topol EJ. Tissue-type plasminogen activator's 10% one-year edge. Cardiology Review. 1997 Dec 1;14(2):41–6.
Williams, P. A., et al. “Tissue-type plasminogen activator's 10% one-year edge.” Cardiology Review, vol. 14, no. 2, Dec. 1997, pp. 41–46.
Williams PA, Califf RM, Topol EJ. Tissue-type plasminogen activator's 10% one-year edge. Cardiology Review. 1997 Dec 1;14(2):41–46.
Published In
Cardiology Review
ISSN
1092-6607
Publication Date
December 1, 1997
Volume
14
Issue
2
Start / End Page
41 / 46
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology